HC Wainwright Has Negative Forecast for MIRM FY2026 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at HC Wainwright dropped their FY2026 earnings estimates for shares of Mirum Pharmaceuticals in a research note issued on Wednesday, November 4th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.61) per share for the year, down from their prior forecast of ($0.37). HC Wainwright has a “Buy” rating and a $202.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.32) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2026 earnings at ($0.68) EPS, Q1 2027 earnings at ($0.60) EPS, Q2 2027 earnings at ($0.50) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at $0.14 EPS, FY2027 earnings at ($1.28) EPS, FY2028 earnings at $2.64 EPS, FY2029 earnings at $6.85 EPS and FY2030 earnings at $10.76 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. The company had revenue of $185.72 million for the quarter, compared to analysts’ expectations of $178.07 million. During the same quarter in the prior year, the company earned $0.05 EPS. The company’s revenue was up 39.6% on a year-over-year basis.

MIRM has been the subject of several other research reports. UBS Group set a $137.00 target price on Mirum Pharmaceuticals in a research note on Thursday, August 27th. Citizens Jmp upped their price target on Mirum Pharmaceuticals from $144.00 to $167.00 and gave the company a “market outperform” rating in a research report on Wednesday. Stifel Nicolaus increased their price target on shares of Mirum Pharmaceuticals from $136.00 to $156.00 and gave the stock a “buy” rating in a report on Wednesday, October 14th. Leerink Partners cut their price objective on shares of Mirum Pharmaceuticals from $154.00 to $140.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, Evercore reaffirmed an “outperform” rating and set a $146.00 price objective on shares of Mirum Pharmaceuticals in a research note on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $154.94.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM opened at $93.54 on Friday. The business’s fifty day moving average is $89.41 and its 200 day moving average is $98.46. The firm has a market cap of $6.07 billion, a price-to-earnings ratio of -6.05 and a beta of 0.75. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.07. Mirum Pharmaceuticals has a 52-week low of $63.23 and a 52-week high of $130.00.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Jupiter Topco LLC purchased a new stake in Mirum Pharmaceuticals during the second quarter valued at about $691,672,000. BlackRock Inc. bought a new position in shares of Mirum Pharmaceuticals during the second quarter valued at about $513,945,000. William Blair Investment Management LLC bought a new position in shares of Mirum Pharmaceuticals during the second quarter valued at about $164,453,000. Janus Henderson Group PLC increased its holdings in shares of Mirum Pharmaceuticals by 14.5% in the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after buying an additional 880,505 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in shares of Mirum Pharmaceuticals in the second quarter worth about $78,434,000.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 6,001 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the transaction, the chief financial officer directly owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $90.00, for a total transaction of $1,800,000.00. Following the completion of the sale, the chief executive officer owned 206,637 shares of the company’s stock, valued at approximately $18,597,330. The trade was a 8.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 116,659 shares of company stock worth $11,404,100 in the last quarter. 8.32% of the stock is owned by insiders.

Key Headlines Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue increased 39.6% year over year to $185.72 million, topping expectations. The company also highlighted new data from its rare liver disease portfolio for an upcoming medical meeting, which could draw attention to its pipeline. Q3 results Portfolio data announcement
• Positive Sentiment: Several firms raised price targets after the earnings update: Citizens JMP to $167, HC Wainwright to $202 and Cantor Fitzgerald to $160; RBC reaffirmed its Outperform rating and $155 target. HC Wainwright also lifted its 2030 EPS forecast, although it cut estimates for earlier years. Citizens JMP rating HC Wainwright rating Cantor Fitzgerald rating
• Neutral Sentiment: CEO Christopher Peetz sold 20,000 shares for $1.8 million under a pre-arranged Rule 10b5-1 plan. The planned sale may be less concerning than an unplanned transaction, though insider selling can draw investor attention. Insider sale report
• Negative Sentiment: Mirum’s Q3 loss of $0.87 per share was wider than the $0.49 consensus loss, despite the revenue beat. Separately, HC Wainwright cut forecasts across Q4 2026 and 2027, including moving its FY2027 estimate from $1.16 earnings to a $1.28 loss, and reduced its FY2028 and FY2029 EPS projections. These revisions point to weaker expected profitability in the near and medium term, even as the firm maintained its Buy rating and $202 target. Q3 earnings call transcript
• Negative Sentiment: Leerink Partners lowered its price target to $140 from $154, though it retained an Outperform rating. Leerink Partners rating

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.